The Kroger Co. (NYSE: KR) has announced the appointment of David Kennerley as its incoming Chief Financial Officer (CFO), effective 3 April 2025. Kennerley, currently Senior Vice President (SVP) and CFO for PepsiCo Europe, will succeed Todd Foley, who has served as interim CFO.

Kennerley will join Kroger on 10 March 2025 as Senior Vice President, working alongside Foley through the end of Kroger’s fiscal year 2024 reporting cycle. Foley will remain with the company as SVP and a member of the senior leadership team, supporting the transition through Kroger’s first quarter.

Smooth Transition Reflects Strong Succession Planning

Rodney McMullen, Kroger’s Chairman and CEO, emphasised the company’s commitment to a seamless leadership transition.

“Consistent with Kroger’s history of thoughtful succession planning, David and Todd will transition seamlessly to ensure Kroger continues to deliver on its go-to-market strategy, providing access to fresh, affordable food for families across America and, by doing so, creating long-term shareholder value,” said McMullen.

This leadership change comes as Kroger continues to focus on driving growth, enhancing operational efficiencies, and delivering value to shareholders.

Todd Foley to Retire from Interim CFO Role After More Than Two Decades at Kroger

With this transition, Todd Foley will step down from his interim CFO role but remain with Kroger’s senior leadership team. McMullen expressed gratitude for Foley’s service and dedication.

“On behalf of our board of directors and senior management team, we thank Todd for stepping into the interim CFO role last year and ensuring the business did not skip a beat,” McMullen stated. “Todd’s contributions to our business and the finance department are wide and deep, and I especially appreciate his care for and commitment to his fellow associates. I wish Todd and his family all the best in the next chapter of their lives.”

Foley’s tenure at Kroger spans more than two decades. He joined the company in 2001 as an audit manager and advanced through several leadership roles, including Vice President and Treasurer (2013), Vice President and Corporate Controller (2017), and Group Vice President and Corporate Controller (2021). Foley became interim CFO in 2024.

Outside Kroger, Foley serves on the board of the Connetic Venture Capital Access Fund and the Board of Advisors for Star Engineering, LLC.

David Kennerley Brings Extensive Global Finance Experience to Kroger

David Kennerley, an accomplished financial leader with nearly 25 years at PepsiCo, brings a wealth of experience spanning U.S. and international markets.

“We look forward to welcoming David to the Kroger team,” said McMullen. “He brings to Kroger deep experience leading a broad cross-section of U.S. and international finance teams, which helped PepsiCo create shareholder value for nearly 25 years.”

Kennerley’s career with PepsiCo began in 2001 in the International Corporate Finance/Treasury Department, managing treasury activities for Western Europe. He later held key leadership roles, including Senior Finance Director for PepsiCo’s Global Beverages Group and SVP Finance for North American Bottling. In 2020, he was named CFO for PepsiCo Europe.

Kennerley expressed excitement for his new role:

“I’m thrilled to be joining Kroger at this exciting time for the business. I look forward to getting started and building on the strong legacy built by Todd and the team. I want to thank PepsiCo for the incredible opportunities I’ve had over the last 24 years. These experiences have been instrumental in paving the way for my new role as the CFO of Kroger.”

Background and Relocation to Cincinnati

Kennerley holds a degree from University College London and is a qualified chartered accountant, having begun his career at Arthur Andersen. He and his family will relocate to Cincinnati as he assumes his new position.

Strategic Leadership for Kroger’s Future Growth

Kennerley’s appointment marks a strategic step for Kroger as the company continues to advance its business strategy, focusing on customer experience, operational excellence, and shareholder value creation.

This leadership transition aligns with Kroger’s long-term vision, ensuring continuity while bringing fresh perspectives from a global leader in the consumer goods sector.

Global sports icon and undefeated boxing legend Floyd Mayweather is stepping into a new ring: performance nutrition. With the launch of his premium supplements line, 101 (One of One), Mayweather brings his championship mindset to the world of wellness. Developed in partnership with supplement experts Magnum Nutraceuticals and guided by entertainment powerhouse WME, this brand isn’t just about supplements—it’s about self-improvement, commitment, and excellence.

“This brand is built to cut through the clutter and give everyone a trusted option,” said Mayweather, co-founder of 101. “I don’t cut corners in the gym, and I won’t cut corners with my nutrition. 101 is designed to deliver results—period.”

A Champion’s Philosophy Meets Cutting-Edge Formulations

The launch of 101 marks Mayweather’s first foray into the wellness market, transforming his passion for fitness into a brand that embodies his drive for peak performance. From the boxing ring to the boardroom, Mayweather’s business ventures—including Mayweather Boxing + Fitness and Mayweather Promotions—centre on empowering individuals to push past their limits.

His entry into the supplements space is no different. With seven premium products formulated for men and women, 101 offers science-backed support for fitness enthusiasts and elite athletes alike.

Introducing the 101 (One of One) Product Line-Up:

• Whey Protein Powder 
  High-quality protein to fuel muscle growth and speed up recovery. Includes prebiotic fibre and digestive enzymes for easy digestion and maximum absorption.
• Sport Pre-Workout 
  A fast-acting blend of NeuroRush and electrolytes to boost stamina, focus, and performance.
• Loaded Pre-Workout
  Designed for serious athletes, with 8g of Citrulline to maximize endurance and energy.
• Creatine Monohydrate 
  Clean, pure ingredients to increase strength and power, plus long-term cognitive and muscle health benefits.
• Greens + Gut Health 
  Over four servings of fruits and vegetables, plus prebiotic fibre for gut support and immune health.
• Hydration 
  On-the-go electrolyte stick packs with taurine to combat fatigue and cramps.
• Peptide Builder 
  Advanced muscle-building capsules powered by PeptiStrong® and DL185™ to promote recovery and fight muscle loss.

A Trusted Collaboration for Champions

The 101 brand is built on a foundation of expertise and trust, thanks to Mayweather’s partnership with Magnum Nutraceuticals, a leader in high-quality supplements for over 20 years.

“Floyd Mayweather’s unmatched work ethic made this collaboration a natural fit,” said Bill Russell, CEO of Magnum Nutraceuticals. “Together, we’ve created a brand that reflects our shared passion for performance and results.”

The Mayweather Standard: Excellence Without Compromise

Floyd Mayweather’s career has been defined by his relentless pursuit of greatness—and that same standard applies to 101 (One of One). Each product is crafted with premium ingredients and scientific formulations to support athletes at every level of their journey.

As Mayweather himself says, “This isn’t just a supplements line. It’s a reflection of my mindset. It’s about pushing past limits—because champions are made by what they do when no one’s watching.”

A new study from the BC Centre for Excellence in HIV/AIDS (BC-CfE) has found that while life expectancy for people with HIV (PWH) in British Columbia, Canada has improved dramatically over the past few decades, women with HIV continue to experience significantly lower life expectancy gains than men.

The study, published in The Lancet Public Health, analysed data from 1996 to 2020 and found that although both men and women have benefited from advances in HIV treatment, the gap in life expectancy between the sexes has widened rather than narrowed. This disparity highlights ongoing socio-economic and healthcare barriers that disproportionately affect women living with HIV.

HIV Treatment Successes, But a Growing Gender Divide

Since 2012, British Columbia has intensified its efforts to combat HIV through the expansion of the Seek and Treat for Optimal Prevention of HIV/AIDS Program (STOP HIV/AIDS). This initiative has led to increased HIV testing, earlier treatment, and improved access to care, resulting in substantial life expectancy gains for people with HIV.

However, the benefits have not been equal. According to the study:

• Life expectancy for men with HIV at age 20 increased from 44 years (1996–2001) to 68 years (2012–2020).
• Life expectancy for women with HIV at age 20 rose from 42 years (1996–2001) to 61 years (2012–2020)—a much smaller increase.
• The life expectancy gap at ages 20 and 40 widened over time, indicating that improvements in healthcare access and treatment have not translated equally across genders.

Dr. Katherine W. Kooij, the study’s lead author, expressed concern about the findings.

“The good news is that both men and women with HIV are living longer, healthier lives thanks to safe and effective HIV treatments available at no cost in British Columbia. However, we initially expected that the life expectancy gap between men and women with HIV would narrow over time. Instead, it has grown.”

Dr. Kooij and her colleagues suspect that socio-structural factors such as healthcare barriers, poverty, housing instability, and stigma may explain why women with HIV continue to face poorer health outcomes.

Women with HIV at Higher Risk of Non-Communicable Diseases

One of the key findings of the study was that women with HIV are 33% more likely to die from non-communicable diseases—including kidney, liver, and lung diseases—compared to men with HIV. This remained true even after accounting for age, socio-economic factors, and past HIV-related health issues.

The research also showed that women with HIV are more likely to live in lower-income neighbourhoods. In the study:

• 12.3% of women with HIV lived in Vancouver’s Downtown Eastside—a neighbourhood known for high rates of unemployment, housing instability, mental health challenges, and substance use. In contrast, only 7.1% of men with HIV lived in this area.
• Women were more likely to report injection drug use as a risk factor for HIV transmission and were more likely to meet the criteria for substance use disorder.

These findings align with a larger Canada-wide study that showed women with HIV are more likely to experience food insecurity, lower income, weaker social support, and discrimination compared to women without HIV.

Additionally, the ongoing opioid crisis in British Columbia has had a disproportionate impact on women with HIV, further contributing to lower life expectancy.

The BC-CfE’s study underscores the need for urgent action to close the life expectancy gap for women with HIV.

“While we continue researching the causes of these disparities, immediate steps must be taken to support women with HIV,” said Dr. Kooij. “Low-barrier healthcare, better housing, and stronger community connections are crucial to improving health outcomes for women.”

The study also emphasizes the importance of screening and prevention efforts for non-communicable diseases among women with HIV. Chronic illnesses, often overlooked in HIV care, are becoming the leading causes of death in this population.

“The life expectancy gap between men and women with HIV should be narrowing—not getting worse,” added Dr. Kooij.

Key Study Insights

• The study included 11,738 men (82.2%) and 2,534 women (17.8%) with HIV, all aged 20 or older.
• Life expectancy was measured at ages 20, 40, and 55 over three periods: 1996–2001, 2002–2011, and 2012–2020.
• The findings contrast with global trends, where women typically outlive men in the general population.

About the BC Centre for Excellence in HIV/AIDS

The BC Centre for Excellence in HIV/AIDS (BC-CfE) is Canada’s largest HIV/AIDS research, treatment, and education centre, internationally recognized for its leadership in combating HIV/AIDS. It pioneered the Treatment as Prevention® (TasP®) strategy, which has influenced global targets, including UNAIDS’ 95-95-95 goal to end the HIV pandemic by 2030.

Beyond HIV, the BC-CfE applies its Targeted Disease Elimination® approach to areas such as viral hepatitis and addiction, working closely with government agencies, healthcare providers, researchers, and communities to improve health outcomes across Canada and globally.

Final Thoughts

This study is a stark reminder that progress in HIV treatment does not automatically translate to equal outcomes for all. While medical advancements have significantly extended life expectancy for people with HIV in British Columbia, women continue to face systemic barriers that limit their ability to benefit fully.

Closing this gap requires a comprehensive approach—one that goes beyond medical care to address the social determinants of health affecting women with HIV. By tackling issues such as housing instability, economic insecurity, and healthcare access, policymakers and healthcare providers can help ensure that all people living with HIV have an equal chance at a longer, healthier life.

Apotex Inc., one of Canada’s largest pharmaceutical companies, has just made a bold move to be at the forefront of this transformation. The company announced the acquisition of CanPrev marking the company’s official entry into the booming health and wellness industry.

This strategic acquisition signals a major step forward for Apotex as it expands beyond traditional pharmaceuticals and into the world of vitamins, supplements, and natural health products—a sector experiencing growing consumer demand. CanPrev, known for its CanPrev, Cyto-Matrix, and Orange Naturals brands, brings a diverse portfolio of over 445 products, available in more than 3,400 retail locations across Canada, from pharmacies and health food stores to grocery chains and online platforms.

A Natural Fit for Apotex’s Growth Strategy

For Apotex, this acquisition isn’t just about expansion—it’s about meeting the changing needs of consumers. Canadians are increasingly looking for natural, preventative health solutions, and with CanPrev’s strong reputation among both consumers and health professionals, Apotex is well-positioned to deliver.

“The acquisition of CanPrev advances Apotex further along on our Journey of Health growth strategy,” said Allan Oberman, President & CEO of Apotex. “It strategically complements our ongoing focus to expand high-value products to consumers and provides us with the opportunity for expansion into select international markets.”

With its established pharmacy presence, Apotex will now be able to broaden its reach into health food stores, naturopathic clinics, and new retail channels, opening doors for even greater accessibility to CanPrev’s trusted products.

A Shared Commitment to Quality & Innovation

For Franco and Tanya Salituro, founders of CanPrev, this acquisition represents an exciting new chapter in their company’s journey.

“We are excited for CanPrev to embark on this new chapter with Apotex, a Canadian-based global health leader,” they shared. “Under Apotex’s ownership, we have an ally and a champion for the natural health industry, opening incredible opportunities for CanPrev to expand its reach and deliver high-quality products to broader audiences.”

Apotex’s established legacy in research, innovation, and pharmaceutical excellence aligns seamlessly with CanPrev’s commitment to science-backed natural health solutions. This union promises exciting developments in product innovation, as well as greater availability of trusted, high-quality supplements for Canadians.

What’s Next?

While CanPrev will continue to operate under its existing brand and distribution channels, consumers can expect increased accessibility to its products across Canada. Additionally, the acquisition sets the stage for future global expansion, bringing CanPrev’s renowned products to new markets through Apotex’s international network.

With the Canadian health and wellness sector on a steady upward trajectory, this acquisition is not just a business move—it’s a reflection of the changing healthcare landscape. As more Canadians prioritize preventative health and natural solutions, Apotex’s entry into this space ensures that trusted, high-quality supplements are more accessible than ever.

The Canadian dollar has recently experienced its longest monthly decline since 2016, posing challenges for Canadian nutraceutical companies and health retailers engaged in international trade, particularly with European and Asian markets. A weaker Canadian dollar increases the cost of importing raw materials and products, potentially impacting profitability. Beyond sourcing locally, businesses can implement several strategies to mitigate the effects of currency depreciation.

1. Utilize Financial Hedging Instruments

Employing financial instruments such as forward contracts and currency options can help manage foreign exchange risk. Forward contracts allow businesses to lock in exchange rates for future transactions, providing cost certainty. Currency options offer the flexibility to exchange currency at a predetermined rate before a specified date, which can be advantageous in volatile markets.

2. Diversify Supplier and Market Base

Expanding your network of suppliers to include those in countries with more stable or favourable exchange rates can reduce reliance on any single currency, helping to manage costs and minimize the impact of currency volatility. Similarly, diversifying your export markets can reduce dependence on a single economy, mitigating risks associated with currency fluctuations.

3. Implement Natural Hedging Strategies

Natural hedging involves matching revenue and expenses in the same foreign currency. For instance, if you have expenses in euros, generating revenue in euros can offset potential losses due to currency fluctuations. This approach reduces the need for currency conversion and minimizes exposure to exchange rate volatility.

4. Adjust Pricing Strategies

Consider adjusting your pricing to reflect increased costs due to currency depreciation. Transparent communication with customers about the reasons for price changes can help maintain trust and loyalty.

5. Enhance Operational Efficiency

Improving operational processes can help offset increased costs. Investing in technology and streamlining operations can lead to cost savings, helping to counterbalance the effects of a weaker currency.

By implementing these strategies, Canadian nutraceutical companies and health retailers can better navigate the challenges posed by a declining Canadian dollar and maintain their competitive edge in the global market.

New Distribution Agreement with Grupo Columbia Strengthens International Presence

Resbiotic Nutrition Inc has entered into a strategic distribution agreement with Grupo Columbia S.A. de C.V., a key player in Mexico’s probiotic and pharmaceutical sectors. Under this collaboration, resB® Lung Support Probiotic will be the first product commercialised across Mexico through Laboratorios Columbia, expanding resbiotic’s footprint in Latin America.

resB®, developed by Dr. C. Vivek Lal, was designed to enhance respiratory function, support gut health, and promote better sleep. Dr. Lal, an expert in pulmonary microbiome research, serves as Director of Clinical Innovation and Director of Pulmonary Microbiome & Innovation Labs at the University of Alabama at Birmingham. He is also the founder of Resbiotic Nutrition, Alveolus Bio Inc., and Able Biolabs, with operations in Birmingham, AL, and Boston, MA.

A Milestone in Resbiotic’s Global Expansion

This agreement marks a major step in resbiotic’s global growth strategy, reinforcing its commitment to delivering science-backed, targeted probiotic solutions to consumers worldwide. By leveraging Laboratorios Columbia’s established salesforce and medical marketing capabilities, resbiotic aims to introduce its formulations to a wider healthcare and consumer audience in Mexico.

“Following our strong brand growth in North America, expanding into Mexico through strategic partnerships is a key milestone in our global distribution strategy,” said Dr. C. Vivek Lal, Founder of resbiotic. “Laboratorios Columbia’s leadership in probiotic-based health solutions makes them an ideal partner to bring our clinically researched formulations to consumers seeking effective microbiome support for chronic conditions.”

Addressing Global Health Challenges with Targeted Microbiome Solutions

Resbiotic’s product line is built around the Gut-X Axis, a concept that highlights the interconnected relationship between the gut and other physiological systems. By modulating targeted biological pathways, resbiotic’s formulations are designed to support overall health and address specific chronic conditions.

Key Products in the Resbiotic Portfolio

• resB® Lung Support Probiotic – The world’s first respiratory probiotic, designed to support lung health in response to pollution, smoking, allergies, and chronic lung conditions.
• resG® Prebeet Prebiotic – A prebiotic blend formulated to promote gut health and metabolic balance.
• resM® GLP-1 Postbiotic – A postbiotic formulation supporting metabolic and gut health through innovative GLP-1 modulation.

A Strong Partnership for the Future

The partnership with Laboratorios Columbia ensures that resbiotic’s formulations will reach health-conscious consumers, healthcare practitioners, and retailers across Mexico. With a growing demand for clinically validated probiotic and biotic-based solutions, this collaboration positions both companies for long-term success in the region.

“We are excited to work with Dr. Lal and resbiotic to bring resB® Lung Support and future innovations to the Mexican market,” said Carlos Quintanilla, Vice President of New Business Development at Laboratorios Columbia. “Consumers are increasingly seeking high-quality, science-backed supplements, and resbiotic’s formulations align perfectly with our mission to offer innovative, evidence-based health solutions.”

By combining scientific expertise with strategic global expansion, resbiotic continues to push the boundaries of microbiome science, ensuring that physician-formulated, research-driven supplements are accessible to a broader international audience.

About Resbiotic Nutrition

Resbiotic Nutrition is a science-driven health and wellness company focused on probiotic, prebiotic, and postbiotic formulations designed to enhance gut, lung, and overall microbiome health. Its physician-formulated products are developed based on rigorous clinical research to address specific health needs through microbiome modulation.

About Laboratorios Columbia

Laboratorios Columbia is a leading pharmaceutical and probiotic manufacturer in Mexico, known for its innovative health solutions and strong presence in the medical and consumer health sectors. With a robust salesforce and medical marketing infrastructure, the company is dedicated to expanding access to clinically validated supplements across the region.